Clinical characteristics of the first known cases of death caused by COVID-19 pneumonia

Aging (Albany NY). 2020 Nov 20;12(22):22405-22412. doi: 10.18632/aging.104171. Epub 2020 Nov 20.

Abstract

Severe pneumonia caused by COVID-19 has resulted in many deaths worldwide. Here, we analyzed the clinical characteristics of the first 17 reported cases of death due to COVID-19 pneumonia in Wuhan, China. Demographics, initial symptoms, complications, chest computerized tomography (CT) images, treatments, and prognoses were collected and analyzed from the National Health Committee of China data. The first 17 reported deaths from COVID-19 were predominately in older men; 82.35% of patients were older than 65 years, and 76.47% were males. The most common initial symptoms were fever or fatigue (14 cases, 82.35%), respiratory symptoms, such as cough (12 cases, 70.59%), and neurological symptoms, such as headache (3 cases, 17.65%). The most common finding of chest CT was viral pneumonia (5 cases, 29.41%). Anti-infectives (11 cases, 64.71%) and mechanical ventilation (9 cases, 52.94%) were commonly used for treatment. Most of the patients (16 cases, 94.12%) died of acute respiratory distress syndrome (ARDS). Our findings show that advanced age and male gender are effective predictors of COVID-19 mortality, and suggest that early interventions to reduce the incidence of ARDS may improve prognosis of COVID-19 pneumonia patients.

Keywords: COVID-19; clinical characteristics; death cases; pneumonia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Infective Agents / therapeutic use
  • COVID-19 / complications
  • COVID-19 / mortality*
  • COVID-19 / therapy
  • COVID-19 / virology
  • China / epidemiology
  • Combined Modality Therapy / methods
  • Female
  • Hospital Mortality
  • Humans
  • Lung / diagnostic imaging
  • Male
  • Middle Aged
  • Pandemics
  • Respiration, Artificial / statistics & numerical data
  • Respiratory Distress Syndrome / diagnosis
  • Respiratory Distress Syndrome / mortality*
  • Respiratory Distress Syndrome / therapy
  • Respiratory Distress Syndrome / virology
  • SARS-CoV-2 / isolation & purification
  • SARS-CoV-2 / pathogenicity*
  • Tomography, X-Ray Computed

Substances

  • Anti-Infective Agents